INDEMNIFICATION AGREEMENTIndemnification Agreement • January 21st, 2022 • Belite Bio, Inc • Pharmaceutical preparations
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made as of ____________, by and between Belite Bio, Inc, an exempted company with limited liability duly incorporated and validly existing under the laws of the Cayman Islands (the “Company”), and __________(Passport/ID Number ____________) (the “Indemnitee”), a [director/an executive officer] of the Company.
EMPLOYMENT AGREEMENTEmployment Agreement • January 21st, 2022 • Belite Bio, Inc • Pharmaceutical preparations • California
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into on __________ by and between Belite Bio, Inc, a Company incorporated in the Cayman Islands (the “Company” and, together with all of its direct or indirect parent companies, subsidiaries, affiliates, or subsidiaries or affiliates of its parent companies, collectively referred to as the “Company Group”), and [ ], an individual, a [ ] citizen with [his/her] passport number being [ ] (the “Executive”).
AMENDMENT TO AMENDED AND RESTATED SHAREHOLDERS AGREEMENTShareholders Agreement • January 21st, 2022 • Belite Bio, Inc • Pharmaceutical preparations • Hong Kong
THIS AMENDMENT TO AMENDED AND RESTATED SHAREHOLDERS AGREEMENT (this “AMENDMENT”) is entered into on November 1, 2021 by and among
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • January 21st, 2022 • Belite Bio, Inc • Pharmaceutical preparations
This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (the "Second Amendment") is made and entered into by and between THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK ("Columbia") and BELITE BIO, INC (“Company”). This Second Amendment shall become effective upon the date that this Second Amendment is signed by both Columbia and Company (the “Second Amendment Effective Date”).
AMENDED AND RESTATED SHAREHOLDERS AGREEMENTShareholders Agreement • January 21st, 2022 • Belite Bio, Inc • Pharmaceutical preparations • Hong Kong
THIS AMENDED AND RESTATED SHAREHOLDERS AGREEMENT (this “Agreement”) is entered into on December 23, 2020 (the “Effective Date”), by and among
THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • January 21st, 2022 • Belite Bio, Inc • Pharmaceutical preparations
This THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Amendment") is made and entered into as of October 24, 2019 (“Third Amendment Effective Date”) by and between Belite Bio, Inc ("Company") and The Trustees of Columbia University in the City of New York ("Columbia").
August 15, 2017 Tom Lin, MD, PhD Lin Bioscience 12F., No. 68, Sec 5, Zhongxiao E. Road, Xinyi Dist., Taipei City 110, Taiwan (R.O.C.) RE: Amendment to the Exclusive Licnese Agreement between Lin Bioscience, Inc. (“Company”) and The Trustees of...License Agreement • January 21st, 2022 • Belite Bio, Inc • Pharmaceutical preparations • New York
The above referenced Exclusive License Agreement (“Agreement”) entered into by the Trustees of Columbia University in the City of New York (“Columbia”) and Lin Bioscience,Inc. (“Company”), dated as of September 13, 2016, is hereby amended, pursuant to Section 22 of the Agreement, as follows:
LBS-008 RESEARCH AND DEVELOPMENT SERVICES AGREEMENTLBS-008 Research and Development Services Agreement • January 21st, 2022 • Belite Bio, Inc • Pharmaceutical preparations
This Research and Development Services Agreement (this “Agreement”), effective as of July 1, 2021 (“Effective Date”), is entered into by and between Belite Bio, Inc, a Cayman corporation, with contact office located at 12F., No.68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan (“Belite Inc”) and Lin BioScience, Inc., a Taiwan corporation, located at 12F., No.68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan (“Lin Inc.”).
SERIES B PREFERRED SHARE PURCHASE AGREEMENTSeries B Preferred Share Purchase Agreement • January 21st, 2022 • Belite Bio, Inc • Pharmaceutical preparations • Hong Kong
SERIES A PREFERRED SHARE PURCHASE AND NOTE CONVERSION AGREEMENTSeries a Preferred Share Purchase and Note Conversion Agreement • January 21st, 2022 • Belite Bio, Inc • Pharmaceutical preparations • Hong Kong
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • January 21st, 2022 • Belite Bio, Inc • Pharmaceutical preparations • New York
AGREEMENT, dated September 13, 2016 (the “Effective Date”), between THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, a New York corporation (“Columbia”), and Lin Biosciences, Inc., a Taiwanese corporation (“Company”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • January 21st, 2022 • Belite Bio, Inc • Pharmaceutical preparations
This FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "Amendment") is made and entered into as of September 1, 2021 (“Fourth Amendment Effective Date”) by and between Belite Bio, Inc ("Company") and The Trustees of Columbia University in the City of New York ("Columbia").
Via Federal Express and electronic mail May 3, 2018 Chairman & CEO Tom Lin, MD, PhD Lin Bioscience, Inc. 12F., No. 68, Sec 5, Zhongxiao E. Road, Xinyi Dist., Taipei City 110, Taiwan (R.O.C.) Re: Exclusive License Agreement between The Trustees of...Belite Bio, Inc • January 21st, 2022 • Pharmaceutical preparations
It is our understanding that LBS is in the process of restructuring and is requesting Columbia's approval for the following assignments of the License Agreement: (i) the assignment by LBS of all of its rights, title, interest, and obligations in and to the License Agreement to its wholly owned Cayman subsidiary Lin BioScience International Ltd ("LBS KY1") (the "First Assignment"), and (ii) the assignment by LBS KY1 of all of its rights, title, interest, and obligations in and to the License Agreement to its wholly owned Cayman subsidiary Lin BioScience Co., Ltd. ("LBS KY2") (the "Second Assignment"). The restructuring and the First Assignment and Second Assignment are illustrated and summarized in Exhibit A hereto, which you have kindly provided to us.
